Spyre Therapeutics, Inc. (SYRE)
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
Spyre Therapeutics' stock rises 73% in a month after mid-stage data show strong efficacy and safety for SPY001 in ulcerative colitis, boosting investor optimism.
Spyre Therapeutics: Strong SPY001 Data Set Up A Catalyst-Rich 2026
Spyre Therapeutics delivered strong Phase 2 data for SPY001, showing rapid, deep efficacy and a clean safety profile in ulcerative colitis. SPY001 achieved a 9.2-point RHI reduction, 40% clinical remission, and 51% endoscopic improvement at 12 weeks, suggesting best-in-class potential. Valuation reflects high expectations for SPY001 and combination regimens, with a $3-4B enterprise value and significant premium for future innovation.
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript
Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms
Spyre Therapeutics, Inc. receives a Strong Buy rating, driven by positive phase 1 data and robust pipeline progress in IBD and rheumatic diseases. SPY001 demonstrated a half-life 4x greater than ENTYVIO, supporting quarterly or twice-yearly dosing for ulcerative colitis in the ongoing phase 2 SKYLINE trial. Accelerated recruitment in the phase 2 SKYWAY RA sub-study brings the anti-TL1A SPY072 data readout forward to Q3 2026, enhancing SYRE's near-term catalysts.
Spyre Therapeutics, Inc. $SYRE Shares Bought by B Group Inc.
B Group Inc. increased its holdings in Spyre Therapeutics, Inc. (NASDAQ: SYRE) by 25.0% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 100,000 shares of the company's stock after buying an additional 20,000 shares during the period. Spyre Therapeutics comprises approximately 1.3% of B
Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript
Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript
Spyre Therapeutics: Validated Targets, Optimized Delivery
Spyre Therapeutics offers a de-risked clinical pipeline and a robust cash runway extending into H2 2028, mitigating near-term financing risk. SYRE's portfolio targets validated mechanisms—alpha-4 beta-7, TL1A, and IL-23—using extended half-life technology to enable infrequent dosing and potential best-in-class efficacy. Recent Phase 1 data show SPY003's 85-day half-life, aligning with other assets for viable combination therapy and supporting platform validation.
Intelligent Development Could Make Spyre Therapeutics Best In Show
Spyre Therapeutics has multiple potential best-in-class antibodies in its pipeline to treat ulcerative colitis, a trial design that tests combinations of these antibodies, and cash to run that trial. SYRE has already begun phase 2 monotherapy work for one of these antibodies, and is planning to initiate phase 2 monotherapy work for another this quarter. SYRE ended Q2'25 with $526.6M in cash and marketable securities, supporting operations for approximately three years.
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward
Spyre Therapeutics, Inc.'s SPY002 and SPY072 drug candidates showed strong safety and TL1A inhibition in a phase 1 study, supporting advancement to phase 2 clinical development. SPY002 targets ulcerative colitis, while SPY072 will address multiple rheumatological conditions, with large market opportunities and key data readouts expected in 2025-2026. The extended half-life of these candidates could enable infrequent dosing, potentially offering a best-in-class advantage over competitors in the autoimmune and inflammatory disorders space.
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%
The average of price targets set by Wall Street analysts indicates a potential upside of 258.3% in Spyre Therapeutics (SYRE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 158.9% upside potential for Spyre Therapeutics (SYRE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
